Yellow zone Gastroenteroloji / Genetik

Hereditary Polyposis Syndromes — Considering and Guiding the Diagnosis

Hereditary polyposis syndromes are rare, but their recognition is valuable not only for the patient but for the ENTIRE FAMILY; a diagnosis in one person can allow at-risk relatives to be protected before the disease manifests. WHEN TO CONSIDER: detection of MULTIPLE COLORECTAL POLYPS, COLORECTAL cancer or polyps at a YOUNG AGE, multiple affected individuals in the family, presence of EXTRACOLONIC findings, and atypical polyp histology.

THE MOST COMMON MISTAKE is REMOVING POLYPS ONE BY ONE AND CONTINUING SURVEILLANCE without investigating the UNDERLYING SYNDROME; while each polyp is dealt with separately, the patient's total polyp burden and family history are not evaluated as a whole. In FAMILIAL ADENOMATOUS POLYPOSIS, colorectal cancer development CAN BE PREVENTED, but this depends on timely surveillance and SURGERY planned at the appropriate time; additionally, the DUODENUM and AMPULLARY REGION are affected, and upper system surveillance should not be neglected.

In HAMARTOMATOUS POLYPOSIS (Peutz-Jeghers, juvenile polyposis) the risk is not limited to the colon, and EXTRACOLONIC CANCER surveillance is required. In case of diagnostic doubt, GENETIC COUNSELING and referral to a specialized center are necessary.

Rapid management

WHERE THE VALUE COMES FROM: the diagnosis concerns not only the patient but the WHOLE FAMILY — a diagnosis made for one person can allow at-risk relatives to be protected BEFORE THE DISEASE EMERGES.
WHEN TO CONSIDER: (1) MULTIPLE colorectal polyps; (2) colorectal cancer or polyps at a YOUNG AGE; (3) MORE THAN ONE affected individual in the family or history of cancer at a young age; (4) EXTRA-COLON findings (bone and dental anomalies, skin lesions, pigmented spots on the LIPS and ORAL MUCOSA, thyroid and brain tumors); (5) ATYPICAL polyp histology (hamartomatous, serrated).
MOST COMMON MISTAKE:
REMOVING POLYPS ONE BY ONE and CONTINUING SURVEILLANCE WITHOUT INVESTIGATING THE UNDERLYING SYNDROME — while each polyp is addressed separately, the TOTAL POLYP BURDEN and FAMILY HISTORY are not evaluated as a whole.
FAMILIAL ADENOMATOUS POLYPOSIS: the development of colorectal cancer CAN BE PREVENTED, but this depends on TIMELY SURVEILLANCE and SURGERY planned AT THE APPROPRIATE TIME; THE UPPER SYSTEM SHOULD NOT BE NEGLECTED — the DUODENUM and AMPULLARY REGION are also involved, and tumors here are an important cause of death after the colon is removed.
HAMARTOMATOUS POLYPOSIS (PEUTZ-JEGHERS, JUVENILE POLYPOSIS): the risk IS NOT LIMITED TO THE COLON — surveillance for breast, pancreas, small intestine, stomach, and gynecological cancers is necessary.
GENETIC COUNSELING and referral to a specialized center are required; genetic testing also guides FAMILY MEMBERS.

Drug	Adult	Pediatric	Route	Duration
Suspicion of a syndrome arises The main reason hereditary polyposis syndromes are overlooked is that clinical attention focuses on individual polyps and the overall picture is missed. Every polyp detected during endoscopy is removed, the pathology result is evaluated, and the next follow-up is planned; this cycle works technically correctly but does not ask the underlying question: why does this patient have so many polyps, and could this be part of a syndrome? If this question is not asked, the patient remains under polyp surveillance for years, but the primary diagnosis is not made, and more importantly, family members continue to live unaware that they are at risk. The features that raise suspicion are clear: an unusually high number of polyps, the patient being young, the presence of multiple affected family members, the presence of extra-colonic findings, and polyps having unusual histology.	Hereditary syndrome should be considered in the presence of MULTIPLE colorectal polyps, polyps or cancer at a YOUNG AGE, more than one affected individual in the family, EXTRA-COLON findings, and atypical polyp histology. Total polyp burden and family history should be evaluated AS A WHOLE.	When a polyp is detected in a child or there is a family history, pediatric gastroenterology and genetic evaluation are required	—	During the evaluation process
Surveillance and surgical timing in familial adenomatous polyposis Familial adenomatous polyposis is one of the rare situations where cancer can truly be prevented, and this arises from the natural course of the disease: hundreds or even thousands of adenomas develop in the colon, and if untreated, it becomes inevitable that one of these will turn into cancer. Therefore, removing polyps one by one becomes meaningless at a certain point and prophylactic surgery comes into play. The main clinical skill here is the timing of the surgery. Surgery done too early can cause significant functional outcomes during critical periods of the patient’s life; being too late increases the risk of cancer development. Therefore, the decision should be made individually and in an experienced center according to polyp burden, patient age, education, and living conditions. Surveillance continues even after surgery because polyps can develop in the remaining bowel tissue.	In FAMILIAL ADENOMATOUS POLYPOSIS, the development of colorectal cancer CAN BE PREVENTED; this depends on timely initiated SURVEILLANCE and PROPHYLACTIC SURGERY planned AT THE RIGHT TIME. The age to start surveillance, the intervals, and the timing of surgery SHOULD BE VERIFIED BY INSTITUTIONAL PROTOCOLS	In this syndrome, surveillance begins in childhood or adolescence; planning is done with pediatric and genetic specialists	—	Lifetime
Upper system surveillance should not be neglected In familial adenomatous polyposis, the most commonly neglected area is the upper digestive system, and the cost of this neglect is high. Since the name of the disease evokes colon polyposis, the impression arises that the problem is solved after the colon is removed, and follow-up becomes relaxed. However, the same genetic disorder also leads to adenoma development in the duodenum and especially in the ampullary region; tumors in this area are one of the leading causes of death in patients who have undergone colon surgery. Therefore, upper system surveillance should be planned as an integral part of the program, and the ampullary region should be evaluated appropriately; a standard endoscopy may not sufficiently show this area. Additionally, in these patients, tumors may also develop in the thyroid, small intestine, and other regions; extra-colonic findings should be systematically evaluated.	In FAMILIAL ADENOMATOUS POLYPOSIS, the DUODENUM and AMPULLARY REGION are also involved; UPPER SYSTEM SURVEILLANCE should also be performed. Tumors in this region are an important cause of death after the colon has been removed. The method and intervals of surveillance SHOULD BE VERIFIED BY INSTITUTIONAL PROTOCOLS	The start time of upper system surveillance is determined with the expert team	Endoscopy	At regular intervals
Extra-colonic risk in hamartomatous polyposis The most common mistake in hamartomatous polyposis syndromes is limiting surveillance to the colon. In these syndromes, polyps are found not only in the colon but also in the small intestine and stomach; however, the main point is that the cancer risk is not limited to the digestive system. In Peutz-Jeghers syndrome, the risk is increased for breast, pancreas, and gynecological cancers; therefore, the surveillance program covers multiple organ systems. A finding that facilitates the recognition of this syndrome is pigmented spots on the lips and oral mucosa; these spots are prominent in childhood and may fade over time, so a history should be taken in adult patients. Additionally, polyps in the small intestine can lead to intussusception requiring emergency surgery; this can be the cause of recurrent abdominal pain, especially in children and young patients.	In hamartomatous syndromes such as PEUTZ-JEGHERS and JUVENILE POLYPOSIS, the risk is NOT LIMITED TO THE COLON; surveillance is required for breast, pancreas, small intestine, stomach, and gynecological cancers. The surveillance program MUST BE VERIFIED BY INSTITUTIONAL PROTOCOL	In these syndromes, findings may appear in childhood; attention is needed for small intestine intussusception	—	Lifetime
Genetic counseling and family screening The value of genetic evaluation in hereditary polyposis syndromes goes beyond the diagnosis of a single patient and this is the main feature that distinguishes the management of these diseases from others. A genetic alteration identified in a patient can be sought in family members with a targeted and much simpler test; individuals found to be carriers are included in a monitoring program, while those shown not to be carriers are spared from unnecessary monitoring. This second point is often overlooked but important; instead of putting all individuals in families with a syndrome under intensive surveillance, identifying who is actually at risk with genetic information is both more effective and less burdensome. Genetic counseling is an integral part of this process; pre- and post-test information, informing the family, and psychological support are included within this scope.	In case of suspected syndrome, GENETIC COUNSELING is planned and referral is made to a specialized center. The genetic test result guides the follow-up not only of the patient but also of FAMILY MEMBERS; relatives at risk should be informed and evaluated	The timing of genetic testing in children is determined by the specialist according to the age of disease onset and monitoring requirements	—	During the diagnostic process
Differentiation of serrated polyposis and other conditions Not all conditions that increase the risk of hereditary colorectal cancer occur with polyposis, and failing to make this distinction is a significant source of confusion. Lynch syndrome is the most common example of this group; in this syndrome, there are not numerous polyps in the colon, so hereditary risk cannot be ruled out just by looking at the number of polyps. Lynch syndrome is assessed with separate criteria, considering family history and examinations performed on tumor tissue. Serrated polyposis is a different condition; in these patients, serrated-type polyps of certain number and size are found in the colon and the risk of colorectal cancer is increased. Recognizing this condition requires consideration of the histological type of polyps; it can be overlooked by looking only at the number. In both cases, the monitoring program differs from the standard screening program and requires specialist evaluation.	SERRATED POLYPOSIS is determined with defined criteria and the risk of colorectal cancer is increased; a monitoring program is also planned. LYNCH SYNDROME is NOT a condition accompanied by polyposis and is assessed with separate criteria (related protocol)	These conditions are evaluated in adult patients	—	During the evaluation process

Alternative

Lynch syndrome does not occur with polyposis and is evaluated with separate criteria; hereditary risk cannot be excluded just by looking at the number of polyps (relevant protocol).
Serrated polyposis can be overlooked if the histological type of polyps is not considered and requires separate monitoring.
In milder forms of familial adenomatous polyposis, the number of polyps is low and diagnosis may be delayed.
In patients with a negative genetic test result but ongoing clinical suspicion, surveillance is continued based on clinical criteria.
Surgical options and timing are individually determined according to polyp burden and the patient's living conditions.
In Peutz-Jeghers syndrome, small bowel polyps can cause intussusception, and small bowel surveillance should be planned separately.
In juvenile polyposis, the coexistence of hereditary hemorrhagic telangiectasia should be investigated.

Red flags

Removing polyps individually without assessing the underlying syndrome → total polyp burden and family history should be evaluated as a whole.
COLORECTAL cancer or polyps at a YOUNG AGE → hereditary syndrome should be investigated; family members are also at risk.
Neglecting UPPER SYSTEM SURVEILLANCE in FAMILIAL ADENOMATOUS POLYPOSIS → tumors in the duodenum and ampullary region are a SIGNIFICANT CAUSE OF DEATH after colon removal.
Relaxation of surveillance after colon removal → polyp development continues in the remaining intestinal tissue and upper system.
Limiting surveillance to the COLON in HAMARTOMATOUS syndromes → surveillance is needed for breast, pancreas, gynecological, and small bowel cancers.
Failure to investigate pigmented spots on the LIPS and ORAL MUCOSA → these spots are prominent in childhood in Peutz-Jeghers syndrome and may FADE over time.
Recurrent abdominal pain in children and young patients → may be due to intussusception from small bowel polyps and may require emergency surgery.
Excluding hereditary risk by polyps NUMBER → LYNCH SYNDROME does not occur with polyposis.
Ignoring the HISTOLOGICAL TYPE of polyps → SERRATED POLYPOSIS can be overlooked when only the number is considered.
Not bringing up GENETIC COUNSELING and family screening → the main value of the diagnosis is protecting at-risk relatives.

Disposition and follow-up

Green zone: Definitive patient, syndrome suspicion: outpatient evaluation, detailed family history taking, planning of genetic counseling, and enrollment in a surveillance program.
Yellow zone: High polyp burden, early-onset cancer, extracolonic findings, or need for surgical planning: referral to a specialized center and multidisciplinary evaluation.
Red zone: Bleeding, obstruction, suspicion of intussusception, or signs of cancer: urgent assessment and interventional planning (relevant protocols).

Key clinical points

READ FIRST — look at the WHOLE rather than individual polyps

SKIPPING MECHANISM: every polyp detected during endoscopy is removed, pathology is evaluated, the next follow-up is planned — this cycle works TECHNICALLY CORRECTLY but DOES NOT ASK THE UNDERLYING QUESTION: "why does this patient have so many polyps, could this be PART OF A SYNDROME?" | When this question is not asked, the patient remains under polyp surveillance FOR YEARS, the primary diagnosis is not made, and MORE IMPORTANTLY, family members live WITHOUT KNOWING THEY ARE AT RISK | FEATURES SUGGESTING SUSPICION: MANY polyps | polyp or cancer at a YOUNG AGE | MORE THAN ONE affected individual in the family | EXTRACOLONIC findings (bone/dental anomalies, skin lesions, pigmented spots in lip-oral mucosa, thyroid and brain tumors) | ATYPICAL histology (hamartomatous, serrated) | VALUE: the diagnosis concerns the ENTIRE FAMILY — at-risk relatives can be protected BEFORE the disease appears

The main reason for missing hereditary polyposis syndromes is that clinical attention focuses on individual polyps, causing the whole picture to be overlooked. In every colonoscopy, polyps detected are removed, pathology results are evaluated, and the next follow-up is planned. This cycle may work perfectly technically, yet it never asks the underlying question: why does this patient develop so many polyps, and could this be part of a syndrome? When the question is not asked, the patient remains under polyp surveillance for years and the primary diagnosis is not made. More importantly, family members continue to live without knowing they are at risk; while for these diseases, the greatest value of a diagnosis is the protection of relatives who have not yet developed the disease. The features that raise suspicion are clear and should be kept in mind at every polyp follow-up.

FAMILIAL ADENOMATOUS POLYPOSIS — cancer is PREVENTABLE but timing is decisive

NATURAL COURSE: hundreds or even thousands of adenomas develop in the colon → if untreated, it becomes INEVITABLE that one of them will turn into cancer | RESULT: removing polyps one by one becomes MEANINGLESS at a certain point and PROPHYLACTIC SURGERY comes into play | THE MAIN CLINICAL SKILL IS TIMING: SURGERY THAT IS TOO EARLY can cause significant FUNCTIONAL OUTCOMES during a critical period of the patient’s life | DELAYING TOO LONG INCREASES CANCER RISK | DECISION: should be made INDIVIDUALLY and in an EXPERIENCED CENTER based on polyp burden, age, EDUCATION, and LIVING CONDITIONS | POSTOPERATIVE SURVEILLANCE CONTINUES — polyps can develop in the remaining bowel tissue | Age, interval, and surgical timing MUST BE VERIFIED BY INSTITUTIONAL PROTOCOL

Familial adenomatous polyposis is one of the rare conditions where cancer can truly be prevented, and this possibility arises from the natural course of the disease. Hundreds, sometimes thousands of adenomas develop in the colon; each has the potential to turn into cancer, so if untreated, it becomes inevitable over time that one of them will undergo malignant transformation. Therefore, a strategy of removing polyps one by one loses its meaning at a certain point, and prophylactic surgery comes into play. The main clinical skill here is not the surgery itself but its timing. Surgery performed too early can cause significant functional outcomes during a critical period of the patient’s educational and social life; delaying too long increases the risk of cancer development. Therefore, the decision should be made individually and in an experienced center.

MOST NEGLECTED AREA — upper gastrointestinal system

REASON FOR NEGLECT: the name of the disease suggests COLON polyposis → after colon removal, the impression arises that the 'problem is solved' and SURVEILLANCE RELAXES | FACT: the same genetic defect leads to adenoma development in the DUODENUM and especially in the AMPULLARY REGION | CRITICAL INFORMATION: tumors in this area are one of the LEADING CAUSES OF DEATH in patients who have UNDERGONE COLON SURGERY | RULE: UPPER SYSTEM SURVEILLANCE should be planned as an INTEGRAL PART of the program | TECHNICAL NOTE: the AMPULLARY REGION needs to be properly evaluated — a STANDARD endoscopy may NOT SHOW this area ADEQUATELY | Additionally, tumors can develop in the THYROID, small intestine, and other regions; extra-colonic findings should be systematically evaluated

In familial adenomatous polyposis, the most frequently neglected area is the upper digestive system, and the cost of this neglect directly reflects on life expectancy. The reason for this neglect is understandable: the name of the disease suggests colon polyposis, and after the colon is removed, the impression arises that the main problem has been solved, leading to lax surveillance. However, the same genetic disorder also causes adenomas to develop in the duodenum and particularly in the ampullary region. Tumors in this area are one of the leading causes of death in patients who have undergone colon surgery; in other words, a patient whose colon problem has been resolved can be lost from the upper system if not monitored. Therefore, upper system surveillance should be planned as an integral part of the program. A technical detail is also important: a standard endoscopy may not be sufficient to properly evaluate the ampullary region.

HAMARTOMATOUS SYNDROMES — risk is not limited to the colon

THE MOST COMMON MISTAKE: LIMITING SURVEILLANCE TO THE COLON | In these syndromes, polyps are also found in the SMALL INTESTINE and STOMACH in addition to the colon — but THE MAIN POINT is that cancer risk is NOT LIMITED TO THE DIGESTIVE SYSTEM | PEUTZ-JEGHERS: RISK OF BREAST, PANCREATIC, AND GYNECOLOGICAL CANCERS IS INCREASED → surveillance covers MULTIPLE ORGAN SYSTEMS | FINDING THAT FACILITATES DIAGNOSIS: pigmented spots on the LIPS and ORAL MUCOSA — PROMINENT IN CHILDHOOD and MAY FADE OVER TIME → in adult patients, HISTORY SHOULD BE TAKEN | EMERGENCY: polyps in the small intestine may lead to INVAGINATION requiring emergency surgery — especially in CHILDREN and YOUNG patients, it may be the cause of RECURRENT ABDOMINAL PAIN | IN JUVENILE POLYPOSIS, the coexistence of hereditary hemorrhagic telangiectasia should be investigated

The most common mistake in hamartomatous polyposis syndromes is limiting surveillance to the colon. In these syndromes, polyps are found not only in the colon but also in the small intestine and stomach; however, the main important point is that the risk of cancer is not limited to the digestive system. In Peutz-Jeghers syndrome, the risk for breast, pancreatic, and gynecological cancers is significantly increased, and the surveillance program should cover multiple organ systems. A finding that facilitates the recognition of this syndrome is pigmented spots on the lips and oral mucosa; these spots are prominent in childhood but may fade over time, so the history should be questioned in adult patients. Additionally, polyps in the small intestine can lead to intussusception, requiring emergency surgery; this can be an unexplained cause of recurrent abdominal pain, especially in children and young patients.

The TWO-FOLD value of genetic testing + non-polyposis conditions

The value of genetic evaluation goes BEYOND THE DIAGNOSIS OF A SINGLE PATIENT | A genetic change identified in a patient can be searched in FAMILY MEMBERS with a targeted and MUCH SIMPLER test | TWO-FOLD BENEFIT: (1) those who are CARRIERS are enrolled in a surveillance program; (2) those who are FREQUENTLY OVERLOOKED — shown NOT TO BE CARRIERS are RELIEVED from unnecessary surveillance burden | That is, instead of placing ALL INDIVIDUALS in a family with the syndrome under intensive surveillance, genetic information determines WHO IS REALLY at risk | GENETIC COUNSELING is an integral part of the process (pre- and post-test information, informing the family, psychological support) | NON-POLYPOSIS CONDITIONS: LYNCH SYNDROME — numerous polyps are NOT FOUND in the colon, so INHERITED RISK CANNOT BE EXCLUDED based on the NUMBER OF POLYPS (relevant protocol) | SERRATED POLYPOSIS — if the HISTOLOGICAL TYPE of polyps is not considered, it may be overlooked

The value of genetic evaluation in hereditary polyposis syndromes goes beyond the diagnosis of a single patient, and this is the key feature that distinguishes the management of these diseases from others. A genetic change identified in one patient can be searched for in family members with a targeted and much simpler test. This has a twofold benefit: individuals found to be carriers are enrolled in a surveillance program, while those shown not to carry it are relieved from unnecessary surveillance burdens. This second point is often overlooked but important. It should also be noted that hereditary colorectal cancer risk does not always present with polyposis; in Lynch syndrome, numerous polyps are not found in the colon, so hereditary risk cannot be excluded by the number of polyps. Serrated polyposis, on the other hand, can be missed if the histological type of the polyps is not considered.

Featured external sources

BSG/ACPGBI/UKCGG hereditary colorectal cancer guideline.Genetic evaluation, colonoscopy, and surgical indications in polyposis syndromes.
Hereditary colorectal cancer guideline: full text.FAP, MAP, upper gastrointestinal surveillance, and details of hamartomatous syndromes.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Hereditary polyposis syndromes are rare, but their recognition is valuable not only for the patient but for the entire family; a diagnosis made in one person can protect at-risk relatives before the disease manifests. Features that raise suspicion for the syndrome are clear: numerous colorectal polyps, colorectal cancer or polyps at a young age, multiple affected individuals in the family, presence of extra-colonic findings, and atypical polyp histology.

The most common mistake is removing polyps one by one and continuing surveillance without ever investigating the underlying syndrome; this technically works, but the total polyp burden and family history are not evaluated as a whole. In familial adenomatous polyposis, the development of colorectal cancer can be prevented, but this depends on timely initiation of surveillance and prophylactic surgery planned at the appropriate time; the timing of surgery should be determined individually.

The most neglected area in this disease is the upper digestive system; tumors in the duodenum and ampullary region are among the leading causes of death after the colon is removed. In hamartomatous polyposis, the risk is not limited to the colon and surveillance is required for breast, pancreas, small intestine, and gynecological cancers.

Genetic counseling and referral to a specialized center are an integral part of the management of these diseases.

Differential diagnosis and assessment

Key considerations

Lynch syndrome does not present with polyposis; hereditary risk cannot be excluded by the number of polyps (relevant protocol).
Serrated polyposis can be overlooked if the histological type of polyps is not considered and requires separate monitoring.
Sporadic multiple adenomas may not meet syndrome criteria but require surveillance (relevant protocol).
Pseudopolyps seen in inflammatory bowel disease should not be confused with adenomas (relevant protocol).
Colonic lymphoid hyperplasia can appear as multiple lesions in children.
Cowden syndrome and other hamartomatous syndromes are distinguished by extra-colonic findings.
In mild forms of familial adenomatous polyposis, the number of polyps may be low, and the diagnosis may be delayed.
The coexistence of juvenile polyposis with hereditary hemorrhagic telangiectasia should be investigated.

Clinical decision reasoning

Why it matters

In the management of hereditary polyposis syndromes, the points that determine the clinical outcome arise from the disease being a familial rather than an individual issue and surveillance being conducted properly. The first point is to consider the diagnosis.

When clinical attention is focused on individual polyps, the underlying problem is not seen; each polyp is removed, pathology is evaluated, and the next control is planned, but the question of why so many polyps have developed is not asked. When this question is not asked, not only is the patient's diagnosis delayed, but family members also live unaware that they are at risk.

The second point is the timing of surgery in familial adenomatous polyposis. Cancer can be prevented in this disease, but this depends on performing the prophylactic surgery at the right time; operating too early results in functional outcomes, whereas delaying too long increases the risk of cancer.

Therefore, the decision should be made individually and at an experienced center. The third point is upper GI surveillance and is the most frequently neglected area.

Because the disease name evokes the colon, follow-up relaxes after the colon is removed; however, duodenal and ampullary tumors are among the leading causes of death in these patients. The fourth point is that in hamartomatous syndromes, the risk is not limited to the colon; surveillance is required for breast, pancreatic, and gynecologic cancers, and small bowel polyps can cause urgent issues like intussusception.

The fifth point is the dual value of genetic testing; those who are carriers are taken into surveillance, while those shown not to be carriers are relieved from unnecessary surveillance burdens. Finally, it should not be forgotten that hereditary risk is not always accompanied by polyposis; in Lynch syndrome, the number of polyps does not increase, and serrated polyposis can be overlooked if the histological type is not considered.

Safety and monitoring

Complications and safety

Critical complications

The development of colorectal cancer becomes inevitable if surveillance is not conducted or if the timing of surgery is delayed.
Duodenal and ampullary tumors are among the leading causes of death after colon surgery.
Small bowel intussusception may require emergency surgery in hamartomatous syndromes.
Extra-colonic cancers (breast, pancreas, thyroid, gynecological) occur with varying frequency depending on the syndrome.
Gastrointestinal bleeding and anemia can develop due to numerous polyps.
Postoperative functional problems and changes in quality of life are particularly significant in young patients.
The development of polyps in the remaining bowel tissue makes postoperative monitoring necessary.
Failure to screen family members leads to the development of preventable cancers.
The psychological effects of genetic diagnosis require counseling.

Special patient populations

Special considerations

The age to start surveillance in children and adolescents is determined according to the syndrome and should be planned with the pediatric team.
The timing of surgery in young adults should be individualized, taking education and life conditions into account.
In women with Peutz-Jeghers syndrome, breast and gynecological cancer surveillance should also be planned.
Genetic counseling and reproductive options should be addressed in patients planning pregnancy.
Patients who have undergone colon surgery should continue upper system surveillance and monitoring of the remaining tissue.
Individuals with a family history of the syndrome but who have not yet been tested should be considered at risk and evaluated.
Patients who test negative for genetics but for whom there is ongoing clinical suspicion should continue surveillance based on clinical criteria.
In juvenile polyposis, the coexistence of hereditary hemorrhagic telangiectasia should also be investigated.

Follow-up and reassessment

Follow-up plan

Surveillance is planned according to the detected syndrome and the patient's treatment status and continues lifelong. In familial adenomatous polyposis, colon surveillance should be carried out at prescribed intervals, polyp burden should be monitored, and the timing of surgery should be regularly reassessed.

Surveillance should not be discontinued in patients who have undergone surgery; polyp development continues in the remaining bowel tissue and requires regular evaluation. Upper system surveillance should continue as an integral part of the program, and the ampullary region should be properly assessed; neglecting this area leads to one of the leading causes of death in these patients.

Extra-colonic findings should be systematically evaluated regarding the thyroid and other organs. In hamartomatous syndromes, surveillance should cover multiple organ systems; separate programs should be planned for the breast, pancreas, gynecological organs, and small intestine.

Recurrent abdominal pain in children and young patients should be evaluated for intussusception. The genetic counseling process should be completed, and it should be verified that family members are informed and assessed; individuals shown not to be carriers should be removed from unnecessary surveillance.

Newly emerging bleeding, signs of obstruction, weight loss, or anemia should be evaluated without waiting for the surveillance interval. Psychological support for the patient and family should not be neglected.